This Viewpoint scratches the surface of how food and pharmaceutical companies are overcoming the multi-faceted challenges posed by AMR. Our main conclusion is that progress is accelerating, but we need all companies for which AMR is a material business risk to work towards implementing best practices.
We recognise that best practices will evolve over time as scientific knowledge of AMR grows and data collection efforts ramp up. In the meantime, transparency about measures to tackle AMR and – for food companies – antibiotic usage is absolutely key. Both the Access to Medicine Foundation and FAIRR play an important role in this regard: their in-depth research into antibiotics is only possible if companies disclose relevant information.
As investors, we need to collectively use this information to enhance our engagement with food and pharmaceutical companies. At BMO GAM, we will continue to commend leading practices and encourage progress in areas where there is scope for improvement.
If governments, companies, investors and civil society succeed in continuing to make incremental progress, we can keep antibiotics working, saving countless human and animal lives.